Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Efficacy of fibrinogen concentrate in major abdominal surgery - A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei.

Roy A, Stanford S, Nunn S, Alves S, Sargant N, Rangarajan S, Smith EA, Bell J, Dayal S, Cecil T, Tzivanakis A, Kruzhkova I, Solomon C, Knaub S, Moran B, Mohamed F.

J Thromb Haemost. 2019 Oct 26. doi: 10.1111/jth.14665. [Epub ahead of print]

PMID:
31654548
2.

Modular one-pot assembly of CRISPR arrays enables library generation and reveals factors influencing crRNA biogenesis.

Liao C, Ttofali F, Slotkowski RA, Denny SR, Cecil TD, Leenay RT, Keung AJ, Beisel CL.

Nat Commun. 2019 Jul 3;10(1):2948. doi: 10.1038/s41467-019-10747-3.

3.

Do patients undergoing cytoreductive surgery and HIPEC for peritoneal malignancy need parenteral nutrition?

Swain DR, Yates AL, Mohamed F, Dayal SP, Tzivanakis A, Cecil TD, Moran BJ.

Pleura Peritoneum. 2018 Oct 2;3(4):20180123. doi: 10.1515/pp-2018-0123. eCollection 2018 Dec 1.

4.

Utilising the Delphi Process to Develop a Proficiency-based Progression Train-the-trainer Course for Robotic Surgery Training.

Collins JW, Levy J, Stefanidis D, Gallagher A, Coleman M, Cecil T, Ericsson A, Mottrie A, Wiklund P, Ahmed K, Pratschke J, Casali G, Ghazi A, Gomez M, Hung A, Arnold A, Dunning J, Martino M, Vaz C, Friedman E, Baste JM, Bergamaschi R, Feins R, Earle D, Pusic M, Montgomery O, Pugh C, Satava RM.

Eur Urol. 2019 May;75(5):775-785. doi: 10.1016/j.eururo.2018.12.044. Epub 2019 Jan 19. Review.

PMID:
30665812
5.

Biological mesh is a safe and effective method of abdominal wall reconstruction in cytoreductive surgery for peritoneal malignancy.

Tzivanakis A, Dayal SP, Arnold SJ, Mohamed F, Cecil TD, Venkatasubramaniam AK, Moran BJ.

BJS Open. 2018 Aug 2;2(6):464-469. doi: 10.1002/bjs5.93. eCollection 2018 Dec.

6.

Use of laparoscopic videos amongst surgical trainees in the United Kingdom.

Celentano V, Smart N, Cahill RA, McGrath JS, Gupta S, Griffith JP, Acheson AG, Cecil TD, Coleman MG.

Surgeon. 2019 Dec;17(6):334-339. doi: 10.1016/j.surge.2018.10.004. Epub 2018 Nov 9.

PMID:
30420320
7.

Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei.

Govaerts K, Chandrakumaran K, Carr NJ, Cecil TD, Dayal S, Mohamed F, Thrower A, Moran BJ.

Eur J Surg Oncol. 2018 Sep;44(9):1371-1377. doi: 10.1016/j.ejso.2018.06.023. Epub 2018 Jul 6.

PMID:
30017331
8.

Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.

Pengelly RJ, Rowaiye B, Pickard K, Moran B, Dayal S, Tapper W, Mirnezami A, Cecil T, Mohamed F, Carr N, Ennis S.

J Mol Diagn. 2018 Sep;20(5):635-642. doi: 10.1016/j.jmoldx.2018.05.002. Epub 2018 Jun 22.

PMID:
29936255
9.

All in: expansion of the acquisition of data for outcomes and procedure transfer (ADOPT) program to an entire SAGES annual meeting hands-on hernia course.

Dort J, Trickey A, Paige J, Schwarz E, Cecil T, Coleman M, Dunkin B.

Surg Endosc. 2018 Nov;32(11):4491-4497. doi: 10.1007/s00464-018-6196-y. Epub 2018 May 1.

PMID:
29717374
10.

LAP-VEGaS Practice Guidelines for Reporting of Educational Videos in Laparoscopic Surgery: A Joint Trainers and Trainees Consensus Statement.

Celentano V, Smart N, McGrath J, Cahill RA, Spinelli A, Obermair A, Hasegawa H, Lal P, Almoudaris AM, Hitchins CR, Pellino G, Browning MG, Ishida T, Luvisetto F, Cingiloglu P, Gash K, Harries R, Harji D, Di Candido F, Cassinotti E, McDermott FD, Berry JEA, Battersby NJ, Platt E, Campain NJ, Keeler BD, Boni L, Gupta S, Griffith JP, Acheson AG, Cecil TD, Coleman MG.

Ann Surg. 2018 Dec;268(6):920-926. doi: 10.1097/SLA.0000000000002725.

PMID:
29509586
11.

Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.

Bignell MB, Mehta AM, Alves S, Chandrakumaran K, Dayal SP, Mohamed F, Cecil TD, Moran BJ.

Colorectal Dis. 2018 Aug;20(8):704-710. doi: 10.1111/codi.14057.

PMID:
29502336
12.

Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival.

Gilani SNS, Mehta A, Garcia-Fadrique A, Rowaiye B, Jenei V, Dayal S, Chandrakumaran K, Carr N, Mohamed F, Cecil T, Moran B.

Int J Hyperthermia. 2018 Aug;34(5):578-584. doi: 10.1080/02656736.2018.1434902. Epub 2018 Feb 12.

PMID:
29431036
13.

Goblet cell carcinomas of the appendix: rare but aggressive neoplasms with challenging management.

Clift AK, Kornasiewicz O, Drymousis P, Faiz O, Wasan HS, Kinross JM, Cecil T, Frilling A.

Endocr Connect. 2018 Feb;7(2):268-277. doi: 10.1530/EC-17-0311. Epub 2018 Jan 15.

14.

Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

García-Fadrique A, Mehta A, Mohamed F, Dayal S, Cecil T, Moran BJ.

J Gastrointest Oncol. 2017 Oct;8(5):915-924. doi: 10.21037/jgo.2017.08.01. Review.

15.

The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin.

Rangarajan K, Chandrakumaran K, Dayal S, Mohamed F, Moran BJ, Cecil TD.

Int J Hyperthermia. 2018 Aug;34(5):559-563. doi: 10.1080/02656736.2017.1384073. Epub 2017 Oct 24.

PMID:
29063804
16.

Peritoneal Involvement Is More Common Than Nodal Involvement in Patients With High-Grade Appendix Tumors Who Are Undergoing Prophylactic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Mehta A, Mittal R, Chandrakumaran K, Carr N, Dayal S, Mohamed F, Moran B, Cecil T.

Dis Colon Rectum. 2017 Nov;60(11):1155-1161. doi: 10.1097/DCR.0000000000000869.

PMID:
28991079
17.

Diagnostic and therapeutic laparoscopy in assessment and management of patients with appendiceal neoplasms.

Tan GHC, Shamji T, Mehta A, Chandrakumaran K, Dayal S, Mohamed F, Carr NJ, Rowaiye B, Cecil T, Moran BJ.

Int J Hyperthermia. 2018 May;34(3):336-340. doi: 10.1080/02656736.2017.1338363. Epub 2017 Jun 28. Review. Erratum in: Int J Hyperthermia. 2018 May;34(3):X.

PMID:
28605985
18.

Risk of Ovarian Involvement in Advanced Colorectal or Appendiceal Tumors Involving the Peritoneum.

Mehta AM, Bignell MB, Alves S, Dayal SP, Mohamed F, Cecil TD, Moran BJ.

Dis Colon Rectum. 2017 Jul;60(7):691-696. doi: 10.1097/DCR.0000000000000791.

PMID:
28594718
19.

Evolution of Surgical Treatment for Rectal Cancer: a Review.

Dayal S, Battersby N, Cecil T.

J Gastrointest Surg. 2017 Jul;21(7):1166-1173. doi: 10.1007/s11605-017-3427-9. Epub 2017 Apr 25. Review.

PMID:
28444558
20.

Acrolein Yields in Mainstream Smoke From Commercial Cigarette and Little Cigar Tobacco Products.

Cecil TL, Brewer TM, Young M, Holman MR.

Nicotine Tob Res. 2017 Jul 1;19(7):865-870. doi: 10.1093/ntr/ntx003.

PMID:
28339569
21.

SAGE(S) advice: application of a standardized train the trainer model for faculty involved in a Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) hands-on course.

Wyles SM, Schwarz E, Dort J, Tariq N, Cecil T, Coleman MG, Paige J, Dunkin BJ.

Surg Endosc. 2017 May;31(5):2017-2022. doi: 10.1007/s00464-017-5463-7. Epub 2017 Mar 13.

PMID:
28289974
22.

Preserving fertility in pseudomyxoma peritonei, a novel approach.

Sheehan LA, Mehta AM, Sawan S, Dayal SP, Mohamed F, Moran BJ, Cecil TD.

Pleura Peritoneum. 2017 Mar 1;2(1):33-36. doi: 10.1515/pp-2016-0024. Epub 2017 Jan 19.

23.

The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.

Tan GH, Novo CA, Dayal S, Chandrakumaran K, Mohamed F, Cecil T, Moran BJ.

Eur J Surg Oncol. 2017 Feb;43(2):388-394. doi: 10.1016/j.ejso.2016.10.009. Epub 2016 Oct 31.

PMID:
27866811
24.

Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.

Di Fabio F, Mehta A, Chandrakumaran K, Mohamed F, Cecil T, Moran B.

Ann Surg Oncol. 2016 Dec;23(13):4316-4321. Epub 2016 Jul 5.

PMID:
27380645
25.

In Reply.

Carr NJ, Cecil TD, González-Moreno S, Mohamed F, Moran BJ, Sobin LH, Sugarbaker PH.

Am J Surg Pathol. 2016 Nov;40(11):1578. No abstract available.

PMID:
27755021
26.

Cytoreductive surgery with intraperitoneal chemotherapy in the management of peritoneal surface malignancy: a pharmacist's perspective.

Mistry P, Mohamed F, Dayal S, Cecil TD, Moran BJ.

Eur J Hosp Pharm. 2016 Jul;23(4):233-238. doi: 10.1136/ejhpharm-2016-000877. Epub 2016 Apr 5. Review.

27.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.

Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ.

Eur J Surg Oncol. 2016 Jul;42(7):1035-41. doi: 10.1016/j.ejso.2016.03.017. Epub 2016 Apr 9.

PMID:
27132072
28.

A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Sargant N, Roy A, Simpson S, Chandrakumaran K, Alves S, Coakes J, Bell J, Knight J, Wilson P, Mohamed F, Cecil T, Moran B.

Transfus Med. 2016 Apr;26(2):118-22. doi: 10.1111/tme.12301. Epub 2016 Mar 31.

PMID:
27030339
29.

Procalcitonin levels predict infectious complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal malignancy.

Saeed K, Dale AP, Leung E, Cusack T, Mohamed F, Lockyer G, Arnaudov S, Wade A, Moran B, Lewis G, Dryden M, Cecil T, Cepeda JA.

Eur J Surg Oncol. 2016 Feb;42(2):234-43. doi: 10.1016/j.ejso.2015.10.004. Epub 2015 Oct 29.

PMID:
26560024
30.

A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.

Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, Taflampas P, Chapman S, Moran BJ; Peritoneal Surface Oncology Group International.

Am J Surg Pathol. 2016 Jan;40(1):14-26. doi: 10.1097/PAS.0000000000000535.

PMID:
26492181
31.

The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy.

Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A.

Colorectal Dis. 2015 Sep;17(9):772-8. doi: 10.1111/codi.12975.

PMID:
25880479
32.

Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.

Di Fabio F, Aston W, Mohamed F, Chandrakumaran K, Cecil T, Moran B.

Colorectal Dis. 2015 Aug;17(8):698-703. doi: 10.1111/codi.12924.

PMID:
25704482
33.

Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases.

Mirnezami R, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N, Mohamed F, Mirnezami AH.

World J Gastroenterol. 2014 Oct 14;20(38):14018-32. doi: 10.3748/wjg.v20.i38.14018. Review.

34.

Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking.

Riss S, Chandrakumaran K, Dayal S, Cecil TD, Mohamed F, Moran BJ.

Eur J Surg Oncol. 2015 Mar;41(3):392-5. doi: 10.1016/j.ejso.2014.09.002. Epub 2014 Sep 6.

PMID:
25238953
35.

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone.

Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, Verwaal VJ, Mohamed F, Mirnezami AH.

Br J Cancer. 2014 Oct 14;111(8):1500-8. doi: 10.1038/bjc.2014.419. Epub 2014 Sep 16.

36.

Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.

Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.

Eur J Surg Oncol. 2015 Mar;41(3):396-9. doi: 10.1016/j.ejso.2014.08.476. Epub 2014 Sep 2.

PMID:
25216980
37.

Benefits of metastasectomy for colorectal cancer.

Cecil T, Mohamed F, Moran B.

BMJ. 2014 Jun 18;348:g4033. doi: 10.1136/bmj.g4033. No abstract available.

PMID:
24944123
38.

Progressively reducing regulatory burden.

Shah VP, Cecil TL, Srinivasan SV, Williams RL.

AAPS J. 2014 Jul;16(4):621-4. doi: 10.1208/s12248-014-9601-z. Epub 2014 Apr 17.

39.

Biorelevant in vitro performance testing of orally administered dosage forms-workshop report.

Reppas C, Friedel HD, Barker AR, Buhse LF, Cecil TL, Keitel S, Kraemer J, Morris JM, Shah VP, Stickelmeyer MP, Yomota C, Brown CK.

Pharm Res. 2014 Jul;31(7):1867-76. doi: 10.1007/s11095-014-1348-9. Epub 2014 Mar 19.

PMID:
24643933
40.

Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.

Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.

Eur J Surg Oncol. 2014 May;40(5):515-520. doi: 10.1016/j.ejso.2013.12.021. Epub 2014 Jan 12.

PMID:
24462284
41.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix.

McConnell YJ, Mack LA, Gui X, Carr NJ, Sideris L, Temple WJ, Dubé P, Chandrakumaran K, Moran BJ, Cecil TD.

Ann Surg Oncol. 2014 Jun;21(6):1975-82. doi: 10.1245/s10434-013-3469-5. Epub 2014 Jan 8.

PMID:
24398544
42.

Treatment of surgically resectable colorectal peritoneal metastases.

Moran BJ, Cecil TD.

Br J Surg. 2014 Jan;101(2):5-7. doi: 10.1002/bjs.9281. Epub 2013 Nov 20. No abstract available.

PMID:
24254364
43.

Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.

Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, Moran BJ.

Dis Colon Rectum. 2013 Dec;56(12):1366-72. doi: 10.1097/DCR.0b013e3182a62b0d.

PMID:
24201390
44.

The use of cardiac output monitoring to guide the administration of intravenous fluid during hyperthermic intraperitoneal chemotherapy.

Thanigaimani K, Mohamed F, Cecil T, Moran BJ, Bell J.

Colorectal Dis. 2013 Dec;15(12):1537-42. doi: 10.1111/codi.12444.

PMID:
24119169
45.

Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Riss S, Mohamed F, Dayal S, Cecil T, Stift A, Bachleitner-Hofmann T, Moran B.

Eur J Surg Oncol. 2013 Sep;39(9):931-7. doi: 10.1016/j.ejso.2013.06.001. Epub 2013 Jun 27. Review.

PMID:
23810280
46.

Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases.

Carr NJ, Finch J, Ilesley IC, Chandrakumaran K, Mohamed F, Mirnezami A, Cecil T, Moran B.

J Clin Pathol. 2012 Oct;65(10):919-23. Epub 2012 Jun 20.

PMID:
22718846
47.

FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms.

Brown CK, Friedel HD, Barker AR, Buhse LF, Keitel S, Cecil TL, Kraemer J, Morris JM, Reppas C, Stickelmeyer MP, Yomota C, Shah VP.

AAPS PharmSciTech. 2011 Jun;12(2):782-94. doi: 10.1208/s12249-011-9634-x. Epub 2011 Jun 18. No abstract available.

48.

A new standard of care for the management of peritoneal surface malignancy.

Mohamed F, Cecil T, Moran B, Sugarbaker P.

Curr Oncol. 2011 Apr;18(2):e84-96.

49.

Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin.

Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.

Dis Colon Rectum. 2011 Mar;54(3):293-9. doi: 10.1007/DCR.0b013e318202f026.

PMID:
21304299
50.

The majority of colorectal resections require an open approach, even in units with a special interest in laparoscopic surgery.

Newman CM, Arnold SJ, Coull DB, Linn TY, Moran BJ, Gudgeon AM, Cecil TD.

Colorectal Dis. 2012 Jan;14(1):29-34; discussion 42-3. doi: 10.1111/j.1463-1318.2010.02504.x.

PMID:
21070568

Supplemental Content

Support Center